Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Sezer, Ahmet; Kılıçkap, Saadettin; Gümüş, Mahmut; Bondarenko, Igor; Özgüroğlu, Mustafa; Gogishvili, Miranda; Türk, Hacı; Çiçin, İrfan; Bentsion, Dmitry; Gladkov, Oleg; Clingan, Philip; Sriuranpong, Virote; Rizvi, Naiyer; Gao, Bo; Li, Siyu; Lee, Sue; Mcguire, Kristina; Chen, Chieh-; Makharadze, Tamta; Paydaş, SEMRA; Nechaeva, Marina; Seebach, Frank; Weinreich, David; Yancopoulos, George; Gullo, Giuseppe; Lowy, Israel; Rietschel, Petra

doi:10.1016/s0140-6736(21)00228-2

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Sezer A., Kılıçkap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., ...Daha Fazla

LANCET, cilt.397, sa.10274, ss.592-604, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 397 Sayı: 10274
Basım Tarihi: 2021
Doi Numarası: 10.1016/s0140-6736(21)00228-2
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Psycinfo, Veterinary Science Database
Sayfa Sayıları: ss.592-604
Çukurova Üniversitesi Adresli: Evet

Özet

Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.